Literature DB >> 16616875

Ebola virus: unravelling pathogenesis to combat a deadly disease.

Thomas Hoenen1, Allison Groseth, Darryl Falzarano, Heinz Feldmann.   

Abstract

Ebola virus (EBOV) causes severe haemorrhagic fever leading to up to 90% lethality. Increasingly frequent outbreaks and the placement of EBOV in the category A list of potential biothreat agents have boosted interest in this virus. Furthermore, development of new technologies (e.g. reverse genetics systems) and extensive studies on Ebola haemorrhagic fever (EHF) in animal models have substantially expanded the knowledge on the pathogenic mechanisms that underlie this disease. Two major factors in EBOV pathogenesis are the impairment of the immune response and vascular dysfunction. Here, we attempt to summarize the current knowledge on EBOV pathogenesis focusing on these two factors and on recent progress in the development of vaccines and potential therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616875     DOI: 10.1016/j.molmed.2006.03.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  64 in total

1.  Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus.

Authors:  Hideki Ebihara; Barry Rockx; Andrea Marzi; Friederike Feldmann; Elaine Haddock; Douglas Brining; Rachel A LaCasse; Don Gardner; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen.

Authors:  Kevin B Spurgers; Tim Alefantis; Brian D Peyser; Gordon T Ruthel; Alison A Bergeron; Julie A Costantino; Sven Enterlein; Krishna P Kota; R C Dutch Boltz; M Javad Aman; Vito G Delvecchio; Sina Bavari
Journal:  Mol Cell Proteomics       Date:  2010-08-11       Impact factor: 5.911

3.  Tsg101 is recruited by a late domain of the nucleocapsid protein to support budding of Marburg virus-like particles.

Authors:  Olga Dolnik; Larissa Kolesnikova; Lea Stevermann; Stephan Becker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

4.  The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus.

Authors:  Catherine L Hunt; Andrey A Kolokoltsov; Robert A Davey; Wendy Maury
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

5.  The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection.

Authors:  Eva Mittler; Larissa Kolesnikova; Bettina Hartlieb; Robert Davey; Stephan Becker
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

6.  Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.

Authors:  Joshua C Johnson; Osvaldo Martinez; Anna N Honko; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  Antiviral Res       Date:  2014-05-09       Impact factor: 5.970

7.  Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition.

Authors:  Osvaldo Martinez; Joshua Johnson; Balaji Manicassamy; Lijun Rong; Gene G Olinger; Lisa E Hensley; Christopher F Basler
Journal:  Cell Microbiol       Date:  2009-09-22       Impact factor: 3.715

8.  Role of Ebola virus VP30 in transcription reinitiation.

Authors:  Miguel J Martínez; Nadine Biedenkopf; Valentina Volchkova; Bettina Hartlieb; Nathalie Alazard-Dany; Olivier Reynard; Stephan Becker; Viktor Volchkov
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

9.  Electron tomography reveals the steps in filovirus budding.

Authors:  Sonja Welsch; Larissa Kolesnikova; Verena Krähling; James D Riches; Stephan Becker; John A G Briggs
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

10.  Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Authors:  Nadia Wauquier; Pierre Becquart; Cindy Padilla; Sylvain Baize; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.